Merit Medical Markets Two New Products; One-Step Centesis Catheter and Inject8 Palm Pad Syringe.Business Editors & Health/Medical Writers SOUTH JORDAN, Utah--(BW HealthWire)--March 4, 2002 Merit Medical Systems Inc. (Nasdaq:MMSI MMSI Maritime Mobile Service Identity MMSI Miniature Munitions/Store Interface MMSI Military Membership Status Identifier ) a manufacturer and marketer of proprietary disposable products Disposable products are items that are not intended by the manufacturer to be reused more than once or a few times as compared to more permanent serviceable and reusable items. Some products that have disposable versions are:
Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. and radiology procedures, announced that it has introduced to market two new products. ONE-STEP(TM) CENTESIS CATHETER The One-Step centesis catheter is the first of three drainage catheter products which the company intends to introduce this year. Comprising a worldwide annual market estimated to be $10 million, centesis catheters are used in a number of procedures to drain large quantities of fluid from cavities within the body such as the abdomen, chest and lungs. The One-Step catheter offers features and benefits which Merit believes are advantageous to clinicians. Introduced in mid-February, sales of the One-Step have already exceeded the company's expectations. INJECT8(TM) PALM PAD SYRINGE The second product, the Inject8 Palm Pad syringe, was developed and recently introduced to address the needs of Merit's customers. This product is an additional model in the company's line of Inject8 coronary control syringes control syringe n. A type of Luer syringe with thumb and finger rings attached to the proximal end of the barrel and to the tip of the plunger, allowing operation with one hand. Also called ring syringe. . These syringes have proven to be an overwhelming success in the cardiology market for diagnostic procedures known as angiograms, of which there are about 5 million performed each year worldwide. The Inject8 is a unique syringe that requires up to 40 percent less injection force because of its smaller barrel size, making it ideal for injecting contrast media by hand through smaller catheters. The Palm Pad version requires less pressure than a larger-barrel syringe, and helps prevent hand fatigue as clinicians forcefully inject contrast media into a catheter under high pressure. The Palm Pad model will be sold primarily in Europe and strengthens Merit's position in market niches where the company's competitors may not be as focused. ABOUT MERIT Founded in 1987, Merit Medical Systems is a publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. engaged in the development, manufacture and distribution of proprietary disposable medical products used in interventional and diagnostic procedures, particularly in cardiology and radiology. The company serves client hospitals worldwide with a domestic and international sales force totaling approximately 70 individuals. Merit Medical employs approximately 1,040 individuals worldwide, with manufacturing facilities in South Jordan and Salt Lake City; Santa Clara Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif.; Angleton, Texas
Angleton is the county seatGR6 of Brazoria County in the U.S. ; and Galway, Ireland. For more information about Merit Medical, visit www.merit.com. Statements contained in this release which are not purely historical are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and are subject to risks and uncertainties such as those described in the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Dec. 31, 2000. Such risks and uncertainties include the company's ability to successfully implement cost-savings programs, acquire or develop new products, technologies, or companies, continue to achieve improvements in gross margins, manage its manufacturing and inventory costs, introduce products in a timely fashion, as well as market acceptance of new products, delays in obtaining regulatory approvals, the impact of changes in foreign currency exchange rates, particularly with respect to the Euro, the ability of the company to increase its inventory turn rate without creating difficulties in product delivery times, price and product competition, and the ability of the company to maintain increased efficiency and provide customer support with its reduced staff. Actual results may differ materially from anticipated results. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion